Ir para o conteúdo principal

Rigel Pharmaceuticals (NASDAQ: RIGL) — Perfil da empresa, notícias e dados financeiros

Logo de Rigel Pharmaceuticals
RIGL Rigel Pharmaceuticals
Rigel Pharmaceuticals primary media
Perfil da empresa

Rigel Pharmaceuticals

Rigel Pharmaceuticals (NASDAQ:RIGL) specializes in discovering, developing, and marketing novel small molecule drugs for the treatment of rare diseases. The company focuses on immunology, oncology, and immune-oncology programs. Their pipeline is rich with projects aiming to target various diseases with unmet medical needs, working on both internally discovered and externally sourced compounds. Objectives include advancing their research to bring innovative therapies to patients while pursuing strategic partnerships and collaborations to expand their reach and capabilities. With a commitment to scientific excellence, Rigel Pharmaceuticals aims to improve the lives of patients suffering from rare and serious diseases through cutting-edge research and drug development.

Resumo

Public USParticipação acionária
1996Ano de fundação
258Funcionários
South San Francisco, United StatesSede
Carregando mapa...
Presença global

Operações

Produtos e/ou serviços de Rigel Pharmaceuticals

  • Fostamatinib, used in treating chronic immune thrombocytopenia, a disorder causing excessive bruising and bleeding due to low platelet counts.
  • R835, an experimental oral IRAK1/4 inhibitor for autoimmune and inflammatory diseases.
  • Fostamatinib's investigation in COVID-19 patients, exploring its efficacy in combating virus-related complications.
  • Collaboration with Eli Lilly for the discovery and development of immunological therapies.

equipe executiva do Rigel Pharmaceuticals

  • Raul R. RodriguezPresident, CEO & Director
  • Dean L. SchornoExecutive VP & CFO
  • Raymond J. FureyExecutive VP, Chief Compliance Officer, General Counsel & Corporate Secretary
  • David A. SantosExecutive VP & Chief Commercial Officer
  • Alison L. HannahExecutive VP & Chief Medical Officer
  • Julie PatelSenior VP of Human Resources
  • Joseph LasagaExecutive VP & Chief Business Officer
  • Tarek SallamVice President of Marketing

Principais indicadores financeiros

Resultados divulgados pela Rigel Pharmaceuticals, em USD.

Cap. de mercado
935,3 mi
Receita (TTM)
276,8 mi
P/L
3.0
LPA (diluído, TTM)
17.1
Dividend yield
—
Margem de lucro
116.3%
Receita e lucro anuais da Rigel Pharmaceuticals
Fim do ano fiscalReceitaResultado operacionalLucro líquido
294,3 mi125,5 mi367 mi
179,3 mi24,2 mi17,5 mi
116,9 mi-20,5 mi-25,1 mi
120,2 mi-55,6 mi-58,6 mi